Sigilon Therapeutics Inc (SGTX)

NASDAQ
Currency in USD
22.47
0.00(0.00%)
Closed·
Showing Sigilon historical data. For real-time data please try another search
Day's Range
22.0823.10
52 wk Range
22.0823.10
Key Statistics
Edit
Prev. Close
22.47
Open
22.9
Day's Range
22.08-23.1
52 wk Range
22.08-23.1
Volume
-
Average Volume (3m)
129.4K
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Sigilon Therapeutics Inc News & Analysis

Show more

Sigilon Company Profile

Sigilon Therapeutics, Inc., a preclinical-stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes, and SIG-001 is in Phase I/II clinical trials to prevent bleeding episodes in patients with moderate to severe hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. The company was incorporated in 2015 and is based in Cambridge, Massachusetts. As of August 11, 2023, Sigilon Therapeutics, Inc. operates as a subsidiary of Eli Lilly and Company.

Earnings

Latest Release
Aug 07, 2023
EPS / Forecast
-3.00 / -0.2312
Revenue / Forecast
5.90M / 3.10M
EPS Revisions
Last 90 days

SGTX Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.